|
Market Closed -
NYSE
04:00:00 25/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 2.750 USD | -1.79% |
|
+1.85% | +52.78% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 221.6 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.06% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 221.6 | 221.6 | 221.6 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.06% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.5x | 55x | 138x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.7x | 3.33x | 3.22x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.7x | 3.33x | 3.22x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.81x | 85.6x | 196x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.750 | 2.750 | 2.750 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/3/22 | 27/2/23 | 14/3/24 | 17/3/25 | 18/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.67x | - | - | - | 226M | |
| 32.72x | 11.87x | 24.12x | 0.6% | 1,026B | |
| 29.94x | 6.66x | 18.64x | 2% | 649B | |
| 33.52x | 7.84x | 16.21x | 2.59% | 468B | |
| 19.75x | 4.81x | 11.92x | 2.76% | 352B | |
| 20.12x | 5.24x | 13.01x | 3.05% | 271B | |
| 21.01x | 4.36x | 12.4x | 2.03% | 256B | |
| 25.68x | 6.7x | 11.94x | 2.48% | 220B | |
| -45.78x | 6.66x | 26.01x | 2.17% | 188B | |
| 11.29x | 4.12x | 8.55x | 4.45% | 170B | |
| Average | 15.99x | 6.47x | 15.87x | 2.46% | 359.93B | |
| Weighted average by Cap. | 23.74x | 7.73x | 17.86x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
